Reference

Comparative activities of AM-833, norfloxacin, ciprofloxacin, and ofloxacin against various experimental infections

Comparative activities of AM-833, norfloxacin, ciprofloxacin, and ofloxacin against various experimental infections. Hirai, K.; Aoyama, H.; Hosaka, M.; Oomori, Y.; Takagi, K.; Suzue, S.; Irikura, T.Chemicals with cas numbers 85721-33-1 and 82419-36-1 also play role. (Cent. Res. Lab., Kyorin Pharm. Co., Ltd., Tochigi, Japan). Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th, Issue Antimicrobial Sect. 2, 1879-80. Edited by: Ishigami, Joji. Univ. Tokyo Press: Tokyo, Japan. (English) 1985. CODEN: 55GNAX. DOCUMENT TYPE: Conference CA Section: 1 (Pharmacology) Section cross-reference(s): 10 The chemotherapeutic efficacy of AM-833 (I) [79660-72-3], a new quinolone, against exptl. infections in animals was compared with that of norfloxacin [70458-96-7], ciprofloxacin [85721-33-1] and ofloxacin [82419-36-1]. The protective effects of a single oral dose of AM-833 on systemic infections with various bacteria in mice were overall greater than those of the other quinolones. AM-833 showed excellent prophylactic activity against Escherichia coli infections. AM-833 was extremely effective against acute pneumonia and ascending urinary tract infections in mice. AM-833 also showed excellent bactericidal activity against granuloma pouch infections with Escherichia coli or Staphylococcus aureus in rats. .

Fleroxacin pharmacokinetics in patients with liver cirrhosis

Fleroxacin pharmacokinetics in patients with liver cirrhosis. Blouin, Robert A.; Hamelin, Bettina A.; Smith, Deborah A.; Foster, Thomas S.; John, William J.; Welker, Horst A. (Coll. Pharm., Univ. Kentucky, Lexington, KY 40536-0082, USA). Antimicrob. Agents Chemother., 36(3), 632-8 (English) 1992. CODEN: AMACCQ. ISSN: 0066-4804. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) In this open-label study, the disposition of fleroxacin in liver disease in 12 healthy male volunteers, 6 male cirrhotics without ascites (group A), and 6 male cirrhotics with ascites (group B) was evaluated.Several substances with their cas registry numbers 79660-71-2 and 79660-72-3 may be metioned in this study. Fleroxacin (400 mg) was administered orally and i.v. to each subject in a random crossover fashion. Fleroxacin was completely absorbed and achieved similar peak concns. in plasma in all three study groups. The vol. of distribution exceeded 1 l/kg in healthy controls and was not affected by liver impairment. Only group B demonstrated differences in the pharmacokinetic parameters evaluated: the systemic and renal clearances of fleroxacin and the renal clearances and clearances of the two major metabolites of fleroxacin formed, N-demethyl fleroxacin and fleroxacin N-oxide, were lower and the half-lives of the parent drug and its metabolites were longer in group B than in healthy controls and group A. The elimination of the two metabolites appeared to be formation rate limited in all three study groups. It was concluded from this study that a 50% redn. in the fleroxacin maintenance dose in patients with liver disease appears justified only in patients with ascites. However, no change in the fleroxacin loading dose is needed in patients with compromised liver function. .